Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery wins Medilink Outstanding Achievement Award

Sygnature Discovery have been named as the winner of the Outstanding Achievement award at the Medilink UK Healthcare Virtual Business Awards 2020, highlighting the company’s success and growth over the last several years.

The aim of the Medilink Business Awards is to highlight the best of the best in the life sciences sector with five categories: Start Up, Export Achievement, Collaboration with the NHS, Innovation and Outstanding Achievement. The virtual awards ceremony took place on 8th October 2020, hosted by comedian and freestyle rapper, Chris Turner, for an afternoon of entertainment, celebration and networking with industry leaders.

Sygnature was a finalist for the national Outstanding Achievement Award, sponsored by Mills & Reeve, after coming first in the regional East Midlands ceremony last year. The national award was received by Sygnature Discovery’s Dr Paul Clewlow, Senior VP, Business Development, Dr Paul Overton, Senior VP, Business Development, and Anders Lindstrom, Director of Marketing.

Paul Clewlow commented:

“What an honour to have won the national Outstanding Achievement Award. Our mission at Sygnature is to enable success for our customers and ultimately to help develop the treatments of the future that will improve the lives of patients across the globe. We have always believed in investing in the brightest and most committed scientists at Sygnature in order to accomplish that mission, and this award is a great recognition of the quality of our work and the determination of our team.”

If you have any questions, would like to find out more about Sygnature Discovery or drug discovery in general then we’d love to hear from you. You can get in touch by using any of the contact forms or by emailing us at

Latest News

View All

Sygnature Discovery and Daewoong Pharma announce research…

New platform set to accelerate early-stage targeted…

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…